Lv2
124 积分 2022-12-06 加入
Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma
10小时前
已完结
Targeting SEZ6L2 in Colon Cancer: Efficacy of Bexarotene and Implications for Survival
11天前
已完结
Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate
2个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
2个月前
已完结
A systematic review of various pKa determination techniques
4个月前
已完结
Beyond cytotoxic potency: disposition features required to design ADC payload
4个月前
已完结
Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE
4个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
5个月前
已完结
皖公网安备34019202002308
